Roche Holding Ltd. (VTX:ROG) has been assigned a CHF 279 price objective by Liberum Capital in a research report issued on Wednesday. The firm currently has a “buy” rating on the healthcare company’s stock. Liberum Capital’s price objective would suggest a potential upside of 13.41% from the stock’s current price.
A number of other equities analysts also recently issued reports on the company. Baader Bank set a CHF 256 price target on Roche Holding and gave the stock a “buy” rating in a research report on Tuesday. HSBC Holdings PLC set a CHF 205 target price on Roche Holding and gave the company a “sell” rating in a research report on Tuesday. Berenberg Bank set a CHF 260 target price on Roche Holding and gave the company a “neutral” rating in a research report on Monday. Goldman Sachs Group, Inc. (The) set a CHF 325 price target on Roche Holding and gave the company a “buy” rating in a report on Monday. Finally, Morgan Stanley set a CHF 260 price target on Roche Holding and gave the company a “neutral” rating in a report on Friday, November 17th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Roche Holding currently has an average rating of “Hold” and an average target price of CHF 261.78.
Roche Holding (VTX:ROG) opened at CHF 246 on Wednesday. Roche Holding has a 1 year low of CHF 218.30 and a 1 year high of CHF 273.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.